Controlled long-term therapy of leprosy with B663 (lamprene, clofazimine) compared with DDS.
D000293:Adolescent; D000328:Adult; D000818:Animals; D002991:Clofazimine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use*; D004285:Dogs; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004361:Drug Tolerance; D004893:Erythema Nodosum / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D009166:Mycobacterium leprae / Q000187:drug effects*; D012880:Skin Pigmentation
D003622:Dapsone; D002991:Clofazimine